Anti-Mouse NKG2A/C/E - Purified in vivo GOLD™ Functional Grade
Antibody Isotype:
IgG2a κ
Antibody Clonality:
Monoclonal
Applications:- Blocking
- Flow Cytometry
- Immunohistochemistry (IHC)
- In Vivo Assay
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
No additional charges, what you see is what you pay! *
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available!
Contact us to find what you can save.
This product comes from:
US.
Typical lead time:
14-21 working days.
Contact us for more accurate information.
- Further Information
- References
- Show All
Further Information
NKG2A/C/E is expressed on NK cells, NKT cells, and activated CD8 T cells.
? 5.0 mg/ml
in vivo GOLD™, Purified in vivo Functional Grade
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94
NKG2A/C/E antibody, clone 20D5, recognizes the NKG2A, NKG2C, and NKG2E isoforms (also known as CD159a, CD159c,m CD159e, respectively) of the NKG2 receptor, belonging to the C-type lectin-like family. NKG2 receptors are expressed at the cell surface as a heterodimer with CD94 and recognize the non-classical class I MHC-1 molecules HLA-E in humans and Qa-1 in mice1-4. NKG2A/C/E are expressed on natural killer (NK) cells, NKT cells, and activated CD8 T cells5-6. Engagement of NKG2A/CD94 transduces an inhibitory signal, blocking NK and CD8 T cell cytotoxicity and promoting self-tolerance7. In contrast, NKG2C/CD94 and NKGE/CD94 are activating receptors8 and bind with lower affinity to HLA-E9. Cancer cells frequently overexpress HLA-E to protect against NK/CD8 T cell killing, and blocking NKG2 receptors in mice promotes anti-tumor immunity and may enhance the cytotoxic potential of other therapeutic antibodies10,11. The NKG2 receptor antibody monalizumab is currently in phase III clinical trials (INTERLINK-1) in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
?95% monomer by analytical SEC, >95% by SDS Page
NKG2a